Compare Stocks

Date Range: 

 Eli Lilly andPfizerNovo Nordisk A/SAbbott LaboratoriesNovartis
SymbolNYSE:LLYNYSE:PFENYSE:NVONYSE:ABTNYSE:NVS
Price Information
Current Price$232.18$44.19$102.10$125.30$83.57
50-Day Moving Average$251.32$45.29$98.50$123.93$90.45
52-Week Low$129.21$33.36$63.22$100.34$77.04
52-Week High$275.87$51.86$107.24$129.70$98.52
MarketRank™
Overall Score2.72.71.42.92.2
Analysis Score2.52.10.02.43.1
Community Score4.84.84.04.84.3
Dividend Score2.53.31.74.22.5
Ownership Score2.52.50.02.50.0
Earnings & Valuation Score1.30.61.30.61.3
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyHold
Consensus Price Target$250.81$43.33N/A$129.42$108.50
% Upside from Price Target8.03% upside-1.94% downsideN/A3.29% upside29.83% upside
Trade Information
Market Cap$222.67 billion$247.76 billion$240.43 billion$222.13 billion$186.92 billion
Beta0.250.740.410.660.54
Average Volume3,512,15130,833,553988,7395,384,7681,887,725
Sales & Book Value
Annual Revenue$24.54 billion$41.91 billion$19.45 billion$34.61 billion$48.66 billion
Price / Sales9.075.9112.366.423.84
Cashflow$8.68 per share$3.01 per share$3.20 per share$5.42 per share$8.24 per share
Price / Cash26.7614.6631.9523.1110.14
Book Value$6.09 per share$11.42 per share$4.12 per share$18.62 per share$24.76 per share
Price / Book38.123.8724.786.733.38
Profitability
Net Income$6.19 billion$9.62 billion$6.46 billion$4.50 billion$8.07 billion
EPS$7.93$2.22$2.76$3.65$5.75
Trailing P/E Ratio34.8118.9733.3735.3021.16
Forward P/E Ratio27.3512.9628.9226.8912.49
P/E Growth1.861.582.812.452.07
Net Margins22.71%23.06%34.17%15.85%17.83%
Return on Equity (ROE)119.12%26.49%72.72%26.75%25.25%
Return on Assets (ROA)15.81%10.73%30.72%12.31%10.74%
Dividend
Annual Payout$3.40$1.56$0.77$1.80$2.08
Dividend Yield1.46%3.53%0.75%1.44%2.49%
Three-Year Dividend Growth42.31%-10.94%13.65%35.85%13.60%
Payout Ratio42.88%70.27%27.90%49.32%36.17%
Years of Consecutive Dividend Growth1 Years1 YearsN/A49 Years1 Years
Debt
Debt-to-Equity Ratio2.21%0.50%0.19%0.52%0.46%
Current Ratio1.15%1.37%1.06%1.79%0.80%
Quick Ratio0.89%1.12%0.80%1.36%0.56%
Ownership Information
Institutional Ownership Percentage81.65%64.93%5.58%72.05%9.90%
Insider Ownership Percentage0.13%0.05%0.07%1.50%0.01%
Miscellaneous
Employees35,00078,50045,323109,000105,794
Shares Outstanding959.03 million5.61 billion2.35 billion1.77 billion2.24 billion
Next Earnings Date10/26/2021 (Confirmed)10/26/2021 (Estimated)10/29/2021 (Estimated)10/20/2021 (Estimated)10/26/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Ex-Novartis Exec Joins Immunology-Focused Biotech Inspired By Keytrudas Side Effects - ScripEx-Novartis Exec Joins Immunology-Focused Biotech Inspired By Keytruda's Side Effects - Scrip
scrip.pharmaintelligence.informa.com - September 23 at 7:29 PM
HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations - Endpoints NewsHHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations - Endpoints News
endpts.com - September 23 at 2:29 PM
Novartis expands gene therapy pipeline with Arctos Medical takeover - PharmaTimesNovartis expands gene therapy pipeline with Arctos Medical takeover - PharmaTimes
pharmatimes.com - September 23 at 9:29 AM
Novartis Acquires Arctos Medical, Expanding Optogenetics Profile - Pharmaceutical Technology MagazineNovartis Acquires Arctos Medical, Expanding Optogenetics Profile - Pharmaceutical Technology Magazine
pharmtech.com - September 23 at 12:12 AM
Novartis Acquires Arctos Medical, Expanding Optogenetics Profile - BioPharm InternationalNovartis Acquires Arctos Medical, Expanding Optogenetics Profile - BioPharm International
biopharminternational.com - September 22 at 7:08 PM
Novartis acquires Arctos Medical to develop gene therapy programme - European Pharmaceutical ReviewNovartis acquires Arctos Medical to develop gene therapy programme - European Pharmaceutical Review
europeanpharmaceuticalreview.com - September 22 at 2:08 PM
Novartis reshuffling doesnt portend a pullback from gene therapy, company says - FiercePharmaNovartis reshuffling doesn't portend a pullback from gene therapy, company says - FiercePharma
fiercepharma.com - September 22 at 2:08 PM
Novartis snaps up another ophthalmic gene therapy company - The Pharma LetterNovartis snaps up another ophthalmic gene therapy company - The Pharma Letter
thepharmaletter.com - September 22 at 9:07 AM
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro DevicesThe Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
finance.yahoo.com - September 22 at 9:07 AM
Top Research Reports for Facebook, Walmart & Novartis - EntrepreneurTop Research Reports for Facebook, Walmart & Novartis - Entrepreneur
entrepreneur.com - September 22 at 12:37 AM
Former Novartis Exec Joins MiroBio to Fight Autoimmune Disease - BioSpaceFormer Novartis Exec Joins MiroBio to Fight Autoimmune Disease - BioSpace
biospace.com - September 21 at 7:35 PM
Top Research Reports for Facebook, Walmart & Novartis - NasdaqTop Research Reports for Facebook, Walmart & Novartis - Nasdaq
nasdaq.com - September 21 at 7:35 PM
So what happened with Novartis gene therapy group? Heres your answer - Endpoints NewsSo what happened with Novartis' gene therapy group? Here's your answer - Endpoints News
endpts.com - September 21 at 7:35 PM
Novartis Adds to Optogenetics Portfolio with Arctos Medical Buy - BioSpaceNovartis Adds to Optogenetics Portfolio with Arctos Medical Buy - BioSpace
biospace.com - September 21 at 7:35 PM
Top Research Reports for Facebook, Walmart & NovartisTop Research Reports for Facebook, Walmart & Novartis
finance.yahoo.com - September 21 at 7:35 PM
Is Novartis AG (NVS) a Stock to Watch After Losing -2.49% This Week? - InvestorsObserverIs Novartis AG (NVS) a Stock to Watch After Losing -2.49% This Week? - InvestorsObserver
investorsobserver.com - September 21 at 2:34 PM
Global Antibiotics Market Size, Analysis, and Top Vendors 2027 – Novartis AG, Bayer AG, Janssen Pharmaceuticals, Astellas Pharma, Inc., Pfizer, Inc. and others – Stillwater Current - Stillwater CurrentGlobal Antibiotics Market Size, Analysis, and Top Vendors 2027 – Novartis AG, Bayer AG, Janssen Pharmaceuticals, Astellas Pharma, Inc., Pfizer, Inc. and others – Stillwater Current - Stillwater Current
stillwatercurrent.com - September 21 at 9:33 AM
Novartis Buys Gene Therapy Firm Arctos Medical in Vision Loss Treatment Push - U.S News & World Report MoneyNovartis Buys Gene Therapy Firm Arctos Medical in Vision Loss Treatment Push - U.S News & World Report Money
money.usnews.com - September 21 at 9:33 AM
Novartis veteran Barth takes the helm at autoimmune biotech MiroBio - FierceBiotechNovartis veteran Barth takes the helm at autoimmune biotech MiroBio - FierceBiotech
fiercebiotech.com - September 21 at 9:33 AM
Diving deeper into inherited retinal disorders, Novartis gobbles up another bite-sized optogenetics biotech - Endpoints NewsDiving deeper into inherited retinal disorders, Novartis gobbles up another bite-sized optogenetics biotech - Endpoints News
endpts.com - September 21 at 4:11 AM
Novartis buys gene therapy firm Arctos Medical in vision loss treatment push - ReutersNovartis buys gene therapy firm Arctos Medical in vision loss treatment push - Reuters
reuters.com - September 21 at 4:11 AM
European Stock Futures Higher; Fed Meeting Looms LargeEuropean Stock Futures Higher; Fed Meeting Looms Large
finance.yahoo.com - September 21 at 4:11 AM
Novartis buys gene therapy firm Arctos Medical in vision loss treatment pushNovartis buys gene therapy firm Arctos Medical in vision loss treatment push
finance.yahoo.com - September 21 at 4:11 AM
Keywords Studios picks Novartis executive Bertrand Bodson as new boss - The TimesKeywords Studios picks Novartis executive Bertrand Bodson as new boss - The Times
thetimes.co.uk - September 20 at 11:11 PM
As Bayer, Novartis stack up their radiopharmaceutical data at #ESMO21, a key debate takes shape - Endpoints NewsAs Bayer, Novartis stack up their radiopharmaceutical data at #ESMO21, a key debate takes shape - Endpoints News
endpts.com - September 20 at 6:10 PM
Novartis (NYSE:NVS) Downgraded by Deutsche Bank Aktiengesellschaft to SellNovartis (NYSE:NVS) Downgraded by Deutsche Bank Aktiengesellschaft to Sell
marketbeat.com - September 20 at 7:53 AM
DateCompanyBrokerageAction
9/20/2021PfizerSVB Leerink
Boost Price Target
9/20/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
9/14/2021PfizerSVB Leerink
Reiterated Rating
9/13/2021PfizerJPMorgan Chase & Co.
Boost Price Target
9/3/2021Novo Nordisk A/SBerenberg Bank
Reiterated Rating
8/31/2021Abbott LaboratoriesBTIG Research
Boost Price Target
8/30/2021Eli Lilly andCowen
Boost Price Target
8/23/2021Novo Nordisk A/SCredit Suisse Group
Reiterated Rating
8/23/2021Novo Nordisk A/SCitigroup
Reiterated Rating
8/23/2021Abbott LaboratoriesCowen
Boost Price Target
8/17/2021Novo Nordisk A/SUBS Group
Reiterated Rating
8/11/2021Novo Nordisk A/SMorgan Stanley
Reiterated Rating
8/9/2021Eli Lilly andArgus
Boost Price Target
8/6/2021Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
8/5/2021Eli Lilly andDZ Bank
Upgrade
8/5/2021Novo Nordisk A/SBarclays
Reiterated Rating
8/5/2021Novo Nordisk A/SBank of America
Upgrade
8/5/2021Novo Nordisk A/SDNB Markets
Upgrade
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/3/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/30/2021PfizerMizuho
Boost Price Target
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/27/2021PfizerTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/22/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021PfizerJPMorgan Chase & Co.
Set Price Target
5/24/2021PfizerThe Goldman Sachs Group
Set Price Target
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/13/2021PfizerThe Goldman Sachs Group
Reiterated Rating
5/12/2021PfizerMizuho
Reiterated Rating
5/11/2021NovartisMorgan Stanley
Reiterated Rating
5/10/2021PfizerMorgan Stanley
Boost Price Target
5/6/2021PfizerMizuho
Downgrade
5/5/2021PfizerSVB Leerink
Boost Price Target
5/5/2021PfizerJPMorgan Chase & Co.
Boost Price Target
5/5/2021PfizerBarclays
Boost Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
4/28/2021NovartisOddo Bhf
Upgrade
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/19/2021NovartisUBS Group
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/7/2021PfizerRoyal Bank of Canada
Initiated Coverage
4/6/2021PfizerThe Goldman Sachs Group
Set Price Target
3/31/2021PfizerThe Goldman Sachs Group
Set Price Target
3/26/2021PfizerSVB Leerink
Lower Price Target
3/23/2021PfizerBerenberg Bank
Reiterated Rating
3/23/2021NovartisSociete Generale
Reiterated Rating
3/22/2021NovartisSanford C. Bernstein
Initiated Coverage
3/16/2021NovartisArgus
Reiterated Rating
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/11/2021Abbott LaboratoriesRaymond James
Boost Price Target
3/10/2021NovartisArgus
Downgrade
2/12/2021Eli Lilly andCowen
Boost Price Target
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
2/2/2021NovartisMorgan Stanley
Reiterated Rating
2/1/2021Eli Lilly andTruist
Boost Price Target
2/1/2021Eli Lilly andMizuho
Boost Price Target
2/1/2021NovartisCowen
Downgrade
1/28/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
1/28/2021Abbott LaboratoriesCowen
Boost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
1/28/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
1/28/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
1/28/2021Abbott LaboratoriesRaymond James
Boost Price Target
1/22/2021NovartisBarclays
Reiterated Rating
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/15/2021NovartisDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/8/2021NovartisMorgan Stanley
Reiterated Rating
12/3/2020NovartisArgus
Boost Price Target
11/25/2020NovartisUBS Group
Reiterated Rating
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/10/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
11/6/2020Novo Nordisk A/SMorgan Stanley
Downgrade
11/3/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
10/15/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
9/29/2020Novo Nordisk A/SBerenberg Bank
Initiated Coverage
9/29/2020NovartisBerenberg Bank
Initiated Coverage
9/23/2020NovartisOddo Bhf
Downgrade
9/10/2020NovartisUBS Group
Upgrade
9/1/2020NovartisMorgan Stanley
Upgrade
8/18/2020Novo Nordisk A/SUBS Group
Reiterated Rating
8/12/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
8/3/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
7/28/2020NovartisMorgan Stanley
Reiterated Rating
7/6/2020Novo Nordisk A/SBank of America
Downgrade
5/18/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.